Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life

Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey

(2019) Pascale Dielenseger et al.   SUPPORTIVE CARE IN CANCER

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy

(2019) Lee Schwartzberg et al.   ONCOLOGIST

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

(2018) L Schwartzberg et al.   ANNALS OF ONCOLOGY

What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study

(2018) Daniel S. Childs et al.   SUPPORTIVE CARE IN CANCER

1681OEvaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data

(2018) M S Aapro et al.   ANNALS OF ONCOLOGY

Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy

(2018) Lee S Schwartzberg et al.   Journal of Comparative Effectiveness Research

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

(2017) Ethan Basch et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists

(2017) Snežana M. Bošnjak et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses

(2017) Rebecca Clark-Snow et al.   SUPPORTIVE CARE IN CANCER

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

(2016) F. Roila et al.   ANNALS OF ONCOLOGY

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

(2016) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study

(2016) Alexander Molassiotis et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting

(2016) Rudolph M. Navari et al.   NEW ENGLAND JOURNAL OF MEDICINE

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

(2016) Matti Aapro et al.   SUPPORTIVE CARE IN CANCER

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

(2016) Karin Jordan et al.   SUPPORTIVE CARE IN CANCER

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

(2015) Massimo Di Maio et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

(2015) Lee S Schwartzberg et al.   LANCET ONCOLOGY

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

(2015) Bernardo L Rapoport et al.   LANCET ONCOLOGY

Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey

(2015) Cheryl Vidall et al.   SUPPORTIVE CARE IN CANCER

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

(2015) Yolanda Escobar et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

(2014) P. J. Hesketh et al.   ANNALS OF ONCOLOGY

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

(2014) R. J. Gralla et al.   ANNALS OF ONCOLOGY

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

(2014) M. Aapro et al.   ANNALS OF ONCOLOGY

Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study

(2014) James W. Gilmore et al.   Journal of Oncology Practice

Practical and statistical issues in missing data for longitudinal patient-reported outcomes

(2013) Melanie L Bell et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

(2012) M. Aapro et al.   ANNALS OF ONCOLOGY

Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

(2012) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting

(2011) Henning Burmeister et al.   SUPPORTIVE CARE IN CANCER

Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

(2010) Margarita Majem et al.   SUPPORTIVE CARE IN CANCER

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

(2010) Steven M. Grunberg et al.   SUPPORTIVE CARE IN CANCER